Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920218 · ClinicalTrials.gov registry record · Phase 2
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
A Phase 2 study of Herpes Zoster, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 11
- Study locations
NCT00920218 is a Phase 2 study of Herpes Zoster that has completed, run by GlaxoSmithKline. The registered enrollment target is 121 participants, below the 2,166-participant average among 16 other Herpes Zoster trials with a reported enrollment target (94% lower). The trial reports 11 study locations across 8 states.
The verdict
NCT00920218, a Phase 2 study of Herpes Zoster, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients.
Conditions Studied
Interventions
- BIOLOGICAL Herpes Zoster Vaccine 1437173A
- BIOLOGICAL Placebo vaccine (saline)
Study Locations (11)
California
- GSK Investigational Site - Duarte
- GSK Investigational Site - San Francisco
Minnesota
- GSK Investigational Site - Minneota
- GSK Investigational Site - Rochester
North Carolina
- GSK Investigational Site - Chapel Hill
- GSK Investigational Site - Durham
Arkansas
- GSK Investigational Site - Little Rock
Massachusetts
- GSK Investigational Site - Boston
New York
- GSK Investigational Site - New York
Ohio
- GSK Investigational Site - Cleveland
Pennsylvania
- GSK Investigational Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2009-07-14 |
| Est. Completion | 2012-03-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00920218
The ClinicalTrials.gov registry entry for NCT00920218 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,166-participant average among 16 other Herpes Zoster trials with a reported enrollment target (94% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 2 interventions - of which Herpes Zoster Vaccine 1437173A is the first listed.
NCT00920218 reports 11 study locations spanning 8 distinct geographic areas - top geographies include California, Minnesota, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00920218 about?
NCT00920218 is a clinical study titled "Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A". The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients.
What is the current status of trial NCT00920218?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2009-07-14. Estimated completion is 2012-03-21.
What conditions does trial NCT00920218 study?
This clinical trial studies the following conditions: Herpes Zoster.
What interventions are being tested in trial NCT00920218?
The interventions under investigation include: Herpes Zoster Vaccine 1437173A (BIOLOGICAL), Placebo vaccine (saline) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00920218?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00920218 being conducted?
This trial has 11 study locations across Arkansas, California, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
-
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
ACTIVE NOT RECRUITING · Phase 2
-
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years
COMPLETED · Phase 2
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.